Physician profile
Mark E Hospodar
NPI 1548222854
$329,181.71
in general payments reported to CMS, 2019-2025
47 companies · $66K in 2025
The $66K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58K · 2020: $32K · 2021: $33K · 2022: $43K · 2023: $44K · 2024: $52K · 2025: $66K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $141K · Food and Beverage: $11K · Consulting Fee: $7,343 · Travel and Lodging: $2,696 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $140,889.50 |
| Food and Beverage | $11,311.26 |
| Consulting Fee | $7,343.00 |
| Travel and Lodging | $2,696.20 |
| Education | $240.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $228,871.42 | 2019-2025 | Mavenclad, Mavenclad |
| Genzyme Corporation | $70,417.80 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $12,763.16 | 2019-2025 | Kesimpta |
| Biogen, INC. | $8,369.75 | 2019-2025 | Tysabri, Vumerity |
| Genentech USA, INC. | $701.63 | 2019-2023 | |
| Abbvie INC. | $671.98 | 2021-2025 | |
| Lilly USA, LLC | $657.15 | 2019-2024 | Kisunla |
| Tg Therapeutics, INC. | $537.48 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $481.71 | 2019-2024 | Ultomiris, Soliris |
| Ucb, INC. | $448.86 | 2019-2024 | Briviact |
| Sk Life Science, INC. | $446.42 | 2020-2024 | Xcopri |
| Janssen Pharmaceuticals, INC | $418.60 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $383.81 | 2019-2022 | |
| Lundbeck LLC | $357.71 | 2019-2024 | Vyepti |
| Horizon Therapeutics Plc | $337.81 | 2023 | Uplizna |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hospodar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.